KRM Ayurveda (KRMAYURVED) H1 FY27 Results: Margin Up 772 bps to 34.95%

KRM Ayurveda (NSE SME: KRMAYURVED) - Share price: ₹219 (close of 17 Nov 2026, screener.in) - Market cap: ₹466 crore - P/E: 16.0 - ROCE: 35.3% (screener.in). The company's own presentation shows 26%.

KRM Ayurveda (KRMAYURVED) H1 FY27 results: operating margin rose to 34.95% from 27.23% as hospital services overtook product sales.

KRM Ayurveda earned a 34.95% operating margin in the six months to September 2026. A year earlier it was 27.23%. Net profit more than doubled (+109.55%) while total income grew 40.10%. The reason is simple: the company now earns most of its money from hospital and clinic services, which pay better than selling medicines.

KRM Ayurveda was incorporated on 3 September 2019. It started as a kidney-care Ayurveda business. It now runs 8 hospitals and 10 day-care centres in 7 states and 10 cities, with 326 beds listed in its 14 November 2026 investor presentation. The shares trade on the NSE SME platform. SME stocks are thinner to trade than mainboard stocks, so buying and selling can be harder.

KRM Ayurveda hospitals now bring in more than product sales

The company sells two things: services (hospital stays, day-care treatment, consultations) and products (its own Ayurvedic medicines). The mix has flipped in three years.

Period Products (₹ crore) Services (₹ crore) Total (₹ crore) Services share --------------- FY24 60.64 6.52 67.16 9.70% FY25 49.23 27.32 76.55 35.70% FY26 47.01 54.68 101.69 53.77% H1 FY27 (April-September 2026) 25.03 41.95 66.98 62.63%

Services went from 9.7% of sales in FY24 to 62.63% in the first half of FY27. The company's own deck says this shift is the reason margins are rising.

KRM Ayurveda H1 FY27 margins: the main growth driver

The company reports total income, EBITDA (operating profit before interest, tax and depreciation) and net profit as below. All figures are consolidated and come from the presentation.

₹ crore H1 FY27 H1 FY26 Change ------------ Total income 68.17 48.65 +40.10% EBITDA 23.82 13.25 +79.81% EBITDA margin 34.95% 27.23% +772 bps Net profit 17.23 8.22 +109.55% Net profit margin 25.28% 16.90% +838 bps EPS (₹) 8.10 5.30 +52.83%

The September quarter alone:

₹ crore Q2 FY27 Q2 FY26 Change ------------ Total income 35.30 23.84 +48.08% EBITDA 11.26 6.88 +63.60% EBITDA margin 31.91% 28.88% +303 bps Net profit 8.15 4.17 +95.37% EPS (₹) 3.83 2.69 +42.38%

Profit grew much faster than income. This is called operating leverage: a hospital's rent, doctors and equipment cost about the same whether 50 or 60 beds are full, so each extra patient adds more profit. Bed occupancy is 60% and average revenue per occupied bed is about ₹8,400 a day. The company has not said what occupancy it needs to reach to keep adding margin.

The one number to remember Income grew 40% but net profit grew 110% because services, which earn more per rupee, rose from 9.7% to 62.63% of sales.

KRM Ayurveda capacity: where the next growth comes from

The existing Gurugram hospital runs at about 90-100% capacity, according to the company. That is the stated reason for the next hospital.

- Sector-47, Gurugram: 80 beds, about 27,500 sq ft. The board approved it on 9 July 2026. It will be paid for entirely from the company's own funds. The deck gives no opening date. - MSS Hospital, Pitampura (New Delhi): 23 beds, 5,631 sq ft, inpatient and outpatient services. Disclosed on 16 June 2026. - Three new day-care centres between April and September 2026: - Janakpuri, New Delhi: began 10 April 2026, 2,761 sq ft, 9-year lease. - Vashi, Navi Mumbai: began 3 September 2026, 2,100 sq ft, 5-year lease. - Nehru Nagar, Ghaziabad: began 23 September 2026, about 3,000 sq ft, 9-year lease. - Quality badges: four more Panchakarma day-care centres (Lucknow, Noida, Patna, Dwarka) received NABH accreditation, so five centres are now accredited. The company also holds CGHS and ECHS empanelment, which lets government employees and ex-servicemen use it, and Ayush Ministry approval to make Ayurvedic medicines.

The deck lists 326 beds in total, split as Delhi 30 and 23, Gurugram 95 and 80, Jaipur 20 and 30, Udaipur 30 and Lucknow 18. The 80-bed Gurugram figure matches the Sector-47 unit that the board only approved in July, and the deck does not say when it opens. Check the exact count of open beds before relying on the 326 number.

The KRM Ayurveda business in short

- Hospitals and day-care centres: inpatient and outpatient Ayurvedic care, Panchakarma (cleansing therapies), signature therapies, wellness programmes (yoga, meditation) and customised herbal medicines. The company calls this an "asset-light" model. - Products: a GMP-certified plant at Kundli, Haryana makes classical and own-brand capsules, tablets, syrups and oils. Top sellers target kidney, liver, digestive, skin and stress problems. - Direct-to-consumer reach: YouTube channels with more than 8 lakh followers, social media advertising and phone consultations that reach patients in other countries. - Team: over 40 physicians, over 71 therapists and more than 500 employees. - Leaders: Dr. Puneet Dhawan is Managing Director and promoter, with over 12 years in kidney and lifestyle-disease treatment. Tanya Dhawan is a non-executive director. Sanchit Hans is whole-time director and has been with the company since 2021. - Acquisition: the company bought Karma Nutravedics. That takes it into nutraceuticals (health supplements) and wellness products.

What KRM Ayurveda management plans next

These are management's own forward-looking statements from the presentation. They are plans, not promises. The company gave no revenue or profit target for FY27 or FY28.

- Build an integrated Ayurvedic platform across hospitals, day-care centres, clinical expertise and wellness products. - Open the 80-bed Sector-47 Gurugram hospital, funded from own money. - Digital health: a 500-seat telemedicine marketing team with an AI-driven patient management system to sell consultations worldwide. - Expand to more tier-II cities and reach the USA through phone consultations. No cities or dates are named. - Medical tourism: wellness packages for overseas patients seeking Ayurveda. - Training: the company is accredited by Rashtriya Ayurveda Vidyapeeth (RAV) to run therapist courses (Panchakarma technician, Prakriti, leech therapy, basti therapy). The first batch finished in FY 2024-25. - Product expansion: more own-brand formulations, wellness lines and a wider distribution network, with brand partnerships. - More NABH accreditations beyond the current five centres.

How big is the market for KRM Ayurveda?

All figures below come from the company's presentation, which cites IMARC and IBEF.

Market Earlier figure Projected figure --------- Ayurvedic products (global, US$) 7.84 billion (FY22) 21.19 billion (FY28) AYUSH market (US$) 50 billion (FY24) 200 billion (FY30) Medical tourism in India (US$) 7.69 billion (2024) 14.31 billion (FY29)

India has only about 1.3 hospital beds per 1,000 people, which the company uses to argue there is room for more capacity. Market forecasts like these are estimates, and they say little about how much KRM Ayurveda itself will earn.

How the KRM Ayurveda valuation compares

KRM Ayurveda has no listed pure-play Ayurveda hospital peer in the screener.in peer table. Screener groups it with large pharma makers. They are far bigger and sell different things, so treat this as a rough yardstick only.

Company Price (₹) P/E Market cap (₹ crore) ROCE --------------- KRM Ayurveda 219.35 15.97 466 35.31% Sun Pharma 1,870 36.46 4,48,676 20.53% Zydus Lifesciences 1,204.20 26.51 1,20,119 21.14% Cipla 1,388 36.11 1,12,135 15.49% Dr Reddy's 1,388 41.41 1,15,936 13.04% Median of the 160-company group n/a 33.35 2,016 14.94%

Data as fetched from screener.in on 18 November 2026. KRM trades at about half the median P/E. A low P/E on a small SME stock can also reflect thin trading, one-time gains or doubts about earnings staying this high.

KRM Ayurveda risks

- Online reputation. The presentation itself includes patient testimonials that answer online claims of "fraud" and "scam" about its kidney treatment. Many reviewers say they read such comments first. The company handles this through content marketing but has not removed the problem. - North India concentration. Management says the company is "currently concentrated in North India". Hospitals are in Delhi, Gurugram, Jaipur, Udaipur and Lucknow. - Capacity gap. The Gurugram unit is almost full until the Sector-47 hospital opens, and no date is given. - Licences and approvals. The business depends on Ayush Ministry approval, NABH accreditation, doctors' registration and CGHS/ECHS empanelment. Losing any of these would hurt. - Receivables and working capital. Screener.in's automated notes say debtor days rose from 56.5 to 81.6 and working capital days from 71.4 to 143. These are screener.in's own computed figures, not the company's. - Integration. Karma Nutravedics is a new line in a crowded market. - Quality while growing. Over 40 physicians and 71 therapists must keep care consistent across 326 listed beds. - Smaller base. The period covers six months. Margins that jumped this fast may not hold, and the company has given no profit guidance.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://nsearchives.nseindia.in/corporate/KRMIPO14112026191323InvestorPresentation14112026.pdf